Table 2.
Baseline Clinicopathological Features According to Histologic Subtypes among EBVaGCs
| Variable | LELC (n=29) | CLR (n=28) | CA (n=19) | p-value† | p-value‡ | p-value§ |
|---|---|---|---|---|---|---|
| Age, yr | ||||||
| Mean±SD | 59.6±9.8 | 58.4±8.1 | 64.6±14.1 | 0.589 | 0.166 | 0.056 |
| <60 | 10 (34.5) | 14 (50.0) | 5 (26.3) | 0.236 | 0.551 | 0.104 |
| ≥60 | 19 (65.5) | 14 (50.0) | 14 (73.7) | |||
| Gender | ||||||
| Male | 26 (89.7) | 25 (89.3) | 15 (78.9) | 0.699 | 0.542 | 0.576 |
| Female | 3 (10.3) | 3 (10.7) | 4 (21.1) | |||
| Location | ||||||
| Proximal | 21 (72.4) | 23 (82.1) | 15 (78.9) | 0.381 | 0.865 | 0.917 |
| Distal | 8 (27.6) | 5 (17.9) | 4 (21.1) | |||
| Tumor size, cm | ||||||
| Mean±SD | 4.1±2.7 | 4.6±2.4 | 5.7±2.2 | 0.421 | 0.027* | 0.108 |
| <5 | 21 (72.4) | 18 (64.3) | 6 (31.6) | 0.509 | 0.005* | 0.028* |
| ≥5 | 8 (27.6) | 10 (35.7) | 13 (68.4) | |||
| Differentiation | ||||||
| Well/moderate | 5 (17.2) | 13 (46.4) | 4 (21.1) | 0.018* | 0.962 | 0.142 |
| Poor | 24 (82.8) | 15 (53.6) | 15 (78.9) | |||
| Lauren’s type | ||||||
| Intestinal | 12 (41.4) | 15 (53.6) | 10 (52.6) | 0.357 | 0.444 | 0.949 |
| Diffuse/mixed | 17 (58.6) | 13 (46.4) | 9 (47.4) | |||
| LVI | ||||||
| Absent | 22 (75.9) | 21 (75.0) | 7 (36.8) | 0.940 | 0.007* | 0.009* |
| Present | 7 (24.1) | 7 (25.0) | 12 (63.2) | |||
| PI | ||||||
| Absent | 13 (44.8) | 9 (32.1) | 3 (15.8) | 0.325 | 0.076 | 0.357 |
| Present | 16 (55.2) | 19 (67.9) | 16 (84.2) | |||
| pTumor depth | ||||||
| pT1/2 | 16 (55.2) | 12 (42.9) | 2 (10.5) | 0.352 | 0.005* | 0.040* |
| pT3/4 | 13 (44.8) | 16 (57.1) | 17 (89.5) | |||
| pLNM | ||||||
| Absent | 19 (65.5) | 14 (50.0) | 4 (21.1) | 0.236 | 0.007* | 0.090 |
| Present | 10 (34.5) | 14 (50.0) | 15 (78.9) | |||
| pTNM | ||||||
| I/II | 24 (82.8) | 19 (67.9) | 3 (15.8) | 0.191 | <0.001* | 0.001* |
| III/IV | 5 (17.2) | 9 (32.1) | 16 (84.2) |
Data are presented as number (%) unless otherwise indicated.
EBV, Epstein-Barr virus; GC, gastric cancer; EBVaGCs, EBV-associated GCs; LELC, lymphoepithelioma-like carcinoma; CLR, adenocarcinoma with Crohn’s disease-like lymphocytic reaction; CA, conventional adenocarcinoma; LVI, lymphatic vascular invasion; PI, perineural invasion; LNM, lymph node metastasis.
*Statistically significant, p<0.05; †LELC vs CLR; ‡LELC vs CA; §CLR vs CA.